Recursion Pharmaceuticals Inc.
RXRX | NASDAQ
$3.98
+$0.01 (+0.25%)
Sep 22, 2026, 10:35 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 7.67M | 6.47M | 35.54M | 5.18M | 19.1M | 14.75M | 4.51M | 26.08M | 14.4M | 13.49M | 10.62M | 10.1M | 11.02M | 12.13M | 13.68M | 13.05M | 7.65M | 5.3M | 2.5M | 2.5M | 2.5M | 2.5M |
Cost of Revenue | 11.49M | 12.49M | 26.88M | 29.59M | 20.16M | 21.83M | 12.79M | 12.08M | 9.2M | 11.17M | 9.88M | 10.88M | 9.38M | 12.45M | 10.84M | 15.41M | 14.23M | 7.8M | n/a | n/a | n/a | n/a |
Gross Profit | -3.82M | -6.02M | 8.66M | -24.42M | -1.06M | -7.08M | -8.28M | 14M | 5.21M | 2.33M | 743K | -775K | 1.63M | -314K | 2.84M | -2.36M | -6.57M | -2.5M | 2.5M | 2.5M | 2.5M | 2.5M |
Operating Income | -134.97M | -128.51M | -108.33M | -172.2M | -176.23M | -191.37M | -183.77M | -98.35M | -100.54M | -96.34M | -98.93M | -99.55M | -81.72M | -69.87M | -60.98M | -62.57M | -66.19M | -55.98M | -64.96M | -46.4M | -40.93M | -30.48M |
Interest Income | 5.31M | 5.96M | 6.25M | 5.54M | 5.44M | 5.56M | 4.62M | 3.83M | 3.27M | 4.05M | 4.52M | 4.98M | 4.96M | 4.66M | 3.68M | 1.83M | 652K | 87K | n/a | 50K | 29K | 16K |
Pretax Income | -131.01M | -122.11M | -108.1M | -162.25M | -171.9M | -202.65M | -178.9M | -95.68M | -98.06M | -92.15M | -97.06M | -93.02M | -76.73M | -65.33M | -57.49M | -60.45M | -65.56M | -55.98M | -64.93M | -47.43M | -43.4M | -30.72M |
Net Income | -131.01M | -117.5M | -108.12M | -162.25M | -171.9M | -202.49M | -178.91M | -95.68M | -97.54M | -91.37M | -93M | -93.02M | -76.73M | -65.33M | -57.49M | -60.45M | -65.56M | -55.98M | -64.93M | -47.43M | -43.4M | -30.72M |
Selling & General & Admin | 41.53M | 34.59M | 33.66M | 41.63M | 46.65M | 54.65M | 77.19M | 37.76M | 31.83M | 31.41M | 30.46M | 29.2M | 28.29M | 22.87M | 19.84M | 19.49M | 21.2M | 21.07M | 19.2M | 15.69M | 13.85M | 8.94M |
Research & Development | 89.61M | 87.9M | 83.34M | 121.06M | 128.64M | 129.63M | 98.33M | 74.6M | 73.93M | 67.56M | 69.48M | 70.01M | 55.06M | 46.68M | 43.98M | 40.84M | 38.44M | 32.44M | 48.29M | 33.25M | 29.62M | 24.11M |
Other Expenses | n/a | n/a | n/a | -14.91M | -120K | n/a | -35K | n/a | -13K | -303K | -267K | -431K | -1K | n/a | n/a | -107K | -21K | -34K | -33K | -34K | -49K | -62K |
Operating Expenses | 131.15M | 122.49M | 117M | 147.78M | 175.17M | 184.28M | 175.49M | 112.36M | 105.75M | 98.67M | 99.67M | 98.78M | 83.35M | 69.55M | 63.82M | 60.22M | 59.62M | 53.48M | 67.46M | 48.9M | 43.43M | 32.98M |
Interest Expense | 309K | 350K | n/a | 833K | 480K | 508K | 605K | 553K | 394K | 20K | 26K | 25K | 26K | 19K | 13K | 13K | 14K | 14K | 2K | 220K | 2.5M | 249K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 142.64M | 134.98M | 143.87M | 177.38M | 195.33M | 206.11M | 188.28M | 124.44M | 114.95M | 109.83M | 109.55M | 109.65M | 92.73M | 82M | 74.66M | 75.63M | 73.84M | 61.28M | 67.46M | 48.9M | 43.43M | 32.98M |
Income Tax Expense | -1K | -4.6M | 20K | 3K | n/a | -158K | 7K | 167K | -523K | -779K | -4.06M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 532.46M | 529.3M | 526.72M | 446.99M | 417.36M | 402.77M | 336.04M | 282.58M | 242.2M | 236.02M | 233.16M | 214.33M | 201.42M | 191.62M | 185.67M | 173.44M | 172.21M | 170.69M | 169.37M | 168.53M | 168.43M | 168.32M |
Shares Outstanding (Diluted) | 532.46M | 529.3M | 526.72M | 446.99M | 417.36M | 402.77M | 336.04M | 282.58M | 242.2M | 236.02M | 233.16M | 214.33M | 201.42M | 191.62M | 185.67M | 173.44M | 172.21M | 170.69M | 169.37M | 168.53M | 168.43M | 168.32M |
EPS (Basic) | -0.25 | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 | -0.53 | -0.34 | -0.40 | -0.39 | -0.40 | -0.43 | -0.38 | -0.32 | -0.31 | -0.34 | -0.38 | -0.33 | -0.38 | -0.28 | -0.26 | -0.18 |
EPS (Diluted) | -0.25 | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 | -0.53 | -0.34 | -0.40 | -0.39 | -0.40 | -0.43 | -0.38 | -0.32 | -0.31 | -0.34 | -0.38 | -0.33 | -0.38 | -0.28 | -0.26 | -0.18 |
EBITDA | -112.53M | -102.09M | -88.62M | -141.21M | -147.57M | -182.81M | -165.34M | -87.92M | -88.7M | -84.76M | -89.48M | -85.41M | -71.16M | -61.58M | -54.27M | -57.44M | -62.76M | -53.2M | -62.36M | -44.77M | -38.57M | -29.07M |
EBIT | -130.7M | -121.76M | -108.1M | -162.25M | -171.42M | -202.14M | -178.29M | -95.12M | -97.67M | -92.13M | -97.03M | -92.99M | -76.7M | -65.31M | -57.48M | -60.43M | -65.55M | -55.97M | -64.95M | -47.21M | -40.9M | -30.47M |
Depreciation & Amortization | 18.17M | 19.67M | 19.48M | 21.04M | 23.85M | 19.33M | 12.95M | 7.2M | 8.97M | 7.38M | 7.55M | 7.58M | 5.54M | 3.73M | 3.21M | 2.99M | 2.79M | 2.77M | 2.58M | 2.44M | 2.33M | 1.4M |
Add to Watchlist
Select watchlists to add or remove RXRX